Table 1.
Demographic and clinicopathological characteristics of the enrolled patients.
| Character | CP dominant | FFP dominant | P value |
|---|---|---|---|
| Number | 11 | 16 | |
| FFP/CP ratio | 0.79 ± 0.04 | 1.43 ± 0.15 | 0.0015 |
| Age(years) | 48.00 ± 2.84 | 51.56 ± 4.21 | 0.53 |
| Gender | 1.00 | ||
| male | 5 | 8 | |
| female | 6 | 8 | |
| PLASMIC score | 0.39 | ||
| 5 | 1 | 0 | |
| 6 | 8 | 11 | |
| 7 | 2 | 5 | |
| Bentley score | 0.43 | ||
| 20-30 | 8 | 8 | |
| >30 | 3 | 8 | |
| Platelet count (×109/L) | 14.45 ± 2.30 | 14.63 ± 1.59 | 0.95 |
| Uncorrected reticulocyte (%) | 14.29 ± 1.82 | 12.57 ± 1.58 | 0.49 |
| MCV (fL) | 93.98 ± 3.67 | 95.75 ± 2.23 | 0.67 |
| INR | 1.07 ± 0.02 | 0.97 ± 0.03 | 0.04 |
| Creatinine (μmol/L) | 86.90 ± 11.94 | 76.59 ± 4.91 | 0.38 |
| Indirect bilirubin (μmol/L) | 29.25 ± 6.52 | 34.16 ± 5.80 | 0.58 |
| Active cancer | 1(9.09%) | 1(6.25%) | 1.00 |
| D-dimer (ug/ml) | 2.17 ± 0.44 | 2.21 ± 0.48 | 0.96 |
| Procedures to complete response | 4.00 ± 0.92 | 8.23 ± 1.63∗ | 0.04 |
| Time to complete response (days) | 5.82 ± 1.39 | 14.08 ± 3.32∗ | 0.04 |
| Steroid use (%) | 11(100%) | 16(100%) | 1.00 |
| Vincristine use (%) | 1(9.09%) | 0(0%) | 0.41 |
| Cyclophosphamide use (%) | 3(27.27%) | 6(37.5%) | 0.69 |
| IVIg use (%) | 4(36.36%) | 10(62.5%) | 0.25 |
| Rituximab use (%) | 1((9.09%) | 2(12.5%) | 1.00 |
IVIg: intravenous immunoglobulin; MCV: mean corpuscular volume; INR: international normalized ratio.